# A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

> **NCT07465757** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Puma Biotechnology, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Small Cell Lung Cancer ( SCLC )

## Interventions

- **DRUG:** Alisertib
- **DRUG:** Alisertib
- **DRUG:** Alisertib
- **DRUG:** Alisertib
- **DRUG:** Alisertib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07465757
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465757, "A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07465757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*